[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastric-cancer-patients-undergoing-gastrectomy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastric-cancer-patients-undergoing-gastrectomy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100612189","ai-assisted-detection-and-staging-of-gastric-cancer-using-contrast-enhanced-ct-100612189",false,"NCT07250347","AI-Assisted Detection and Staging of Gastric Cancer Using Contrast-Enhanced CT","Langue and Imaging-integrated Foundation Model for Gastric Cancer Detection and Staging Via Contrast-Enhanced CT: a Multicenter Study","Inclusion Criteria:\n\n1. pathologically confirmed gastric cancer;\n2. preoperative contrast-enhanced CT performed;\n3. no evidence of distant metastasis on baseline staging;\n4. curative-intent management with complete postoperative histopathology.\n\nExclusion Criteria:\n\n1. prior treatment before surgery;\n2. non-diagnostic or poor-quality CT precluding evaluation.","ALL","18 Years","85 Years",{"count":20,"type":21},8000,"ESTIMATED","OBSERVATIONAL","Accurate preoperative assessment of gastric cancer stage guides eligibility for endoscopic resection, extent of gastrectomy and lymphadenectomy, selection for neoadjuvant therapy, and use of staging laparoscopy. Contrast-enhanced CT (CECT) is guideline-endorsed for initial staging, yet performance varies across institutions and readers. This study will evaluate an artificial-intelligence (AI) system that analyzes routine CECT to detect gastric cancer and assign four-class T stage (T1-T4) and N stage (N0-N3) .",[25,26],"Gastric Cancer Stage","Gastric Cancer Patients Undergoing Gastrectomy",[28,29,30,31,32],"Gastric cancer","stage","artificial-intelligence","detection","contrast-enhanced CT","RECRUITING","2025-11-24",{"date":36,"type":37},"2025-11-26","ACTUAL",{"date":39,"type":37},"2025-08-01",{"date":41,"type":21},"2028-12-30",{"name":43,"class":44},"The First Affiliated Hospital with Nanjing Medical University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":45},"100611172","single-port-robotic-radical-gastrectomy-for-gastric-cancer-100611172","NCT07237126","Single-port Robotic Radical Gastrectomy for Gastric Cancer","Efficacy and Safety Assessment of Single-port Robotic Radical Gastrectomy for Gastric Cancer: a Phase 2a Trial Based on the IDEAL Framework","Inclusion Criteria:\n\n* (1) Age: 18-75 years; (2) Histologically confirmed gastric adenocarcinoma by endoscopic biopsy; (3) Preoperatively staged as either endoscopically unresectable T1, or cT2-4a with or without nodal involvement (N-\u002F+), and no distant metastasis (M0), according to the 7th edition of the AJCC Cancer Staging Manual; (4) Eligible for potentially curative surgical resection; (5) Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1; (6) American Society of Anesthesiologists (ASA) physical status classification of I-III; (7) Provision of written informed consent.\n\nExclusion Criteria:\n\n* (1) Pregnant or lactating women; (2) Severe psychiatric disorder; (3) History of prior upper abdominal surgery; (4) Previous gastrectomy, endoscopic submucosal dissection (ESD), or endoscopic mucosal resection (EMR); (5) Preoperative imaging showing regional lymphadenopathy with lymph node(s) larger than 3 cm in diameter; (6) History of another primary malignancy within the past 5 years; (7) Prior neoadjuvant chemotherapy or radiotherapy; (8) History of cerebrovascular or cardiovascular event (e.g., stroke or myocardial infarction) within the past 6 months; (9) Systemic corticosteroid use for more than one month within the past month; (10) Requirement for concomitant surgery for other conditions; (11) Need for emergency surgery due to gastric cancer-related complications (e.g., bleeding, obstruction, or perforation); (12) Participation in another interventional clinical trial previously; (13) Active severe infectious disease; (14) Severe systemic disease.","75 Years",{"count":55,"type":21},20,"INTERVENTIONAL",[58],"NA","This study is a single-center, phase 2a exploratory clinical study based on IDEAL framework. The intraoperative and postoperative complications were analyzed to evaluate the safety, feasibility and clinical efficacy of single-port robot-assisted gastric tumor resection.",[26],[62,28,63],"Single-port robotic","Radical Gastrectomy","NOT_YET_RECRUITING","2025-11-16",{"date":67,"type":37},"2025-11-19",{"date":69,"type":21},"2025-11-20",{"date":71,"type":21},"2027-11-20",{"name":73,"class":44},"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":56,"phases":85,"briefSummary":86,"conditions":87,"keywords":92,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":45},"100608461","peri-habilitation-for-patients-with-gastric-cancer-100608461","NCT07201857","Peri-habilitation for Patients With Gastric Cancer","Peri-habilitation to Enhance Treatment Outcomes and Postoperative Recovery in Patients With Gastric Cancer","Inclusion Criteria:\n\n* Patients aged 65 years or older who have been diagnosed with gastric cancer and are scheduled to undergo surgical treatment or chemotherapy.\n\nExclusion Criteria:\n\n* Patients with severe conditions who are unable to undergo the intervention prior to surgical treatment or chemotherapy.\n* Patients with physical (e.g., musculoskeletal) or mental disorders that make participation in or continuation of the program impossible.\n* Patients judged to be at risk of additional physical burden from the intervention.","65 Years","90 Years",{"count":84,"type":21},30,[58],"This study aims to evaluate the clinical applicability of a peri-habilitation program in patients with gastric cancer by applying nutritional intervention for approximately two weeks before surgery and a combined exercise and nutrition intervention for about three weeks after hospital discharge, and by analyzing its effects on the prevention of postoperative complications and recovery.",[88,89,26,90,91],"Gastric Cancer (Diagnosis)","Gastric Cancer Patient","Gastric Cancer Patients Undergoing Minimally Invasive Gastrectomy","Gastric Cancer Patients Undergoing Laparoscopic Gastrectomy",[93,94,95,96],"peri-habilitation","gastric cancer","postoperative recovery","exercise intervention","2025-09-23",{"date":99,"type":37},"2025-10-01",{"date":101,"type":21},"2025-10-15",{"date":103,"type":21},"2026-12-31",{"name":105,"class":44},"Korea University Anam Hospital"]